Popular

Supreme Court Clarifies Scope of Drug Offense Sentencing Relief Under the First Step Act

The Government Spending Oversight Act and the Future of the Pandemic Response Accountability Committee

Tax-Advantaged Savings Accounts: Overview and Policy Considerations

Wastewater and Drinking Water: Committee Deadlines for EPA’s Administration of “Earmarks”

Service-Disabled Veteran-Owned Small Business Procurement Program

Congressional Court Watcher: Recent Appellate Decisions of Interest to Lawmakers (March 28–April 3, 2022)

Congressional Court Watcher: Recent Appellate Decisions of Interest to Lawmakers (April 18–April 24, 2022)

Congressional Court Watcher: Recent Appellate Decisions of Interest to Lawmakers (Nov. 28–Dec. 4, 2022)

NATO Enlargement to Sweden and Finland

Medicare Part B: Enrollment and Premiums

Restricting TikTok (Part II): Legislative Proposals and Considerations for Congress

Small Business Administration Reauthorization: Issues for Congress

Agriculture and Related Agencies: FY2024 Appropriations

To Fee or Not to Fee: Supreme Court to Consider Attorneys’ Fees in Patent Disputes

Supreme Court to Address No-Appeal Provision for Patent Challenges

When Can Copyright Holders Sue?: Supreme Court to Resolve Circuit Split on Copyright Registration

Do “Secret Sales” Trigger the On-Sale Bar to Patentability under the America Invents Act?

Down to a Science (and Technology): Tribe’s Patent Assignment Deals Extend to High-Tech Patents

SCOTUS Considers Federal Court Jurisdiction Over Constitutional Challenges to Pending Agency Actions

Supreme Court to Consider the Meaning of “Knowingly” Under the False Claims Act

Smith v. Spizzirri: Supreme Court to Consider Whether Federal Courts May Dismiss a Lawsuit Subject to Arbitration

COVID-19: Potential Implications for International Security Environment—Overview of Issues and Further Reading for Congress

Deployable Federal Assets Supporting Domestic Disaster Response Operations: Summary and Considerations for Congress

Defining Active Ingredient: The U.S. Food and Drug Administration’s Legal Interpretation of Regulatory Exclusivities

The Gambia